Development of the IL-12/23 antagonist ustekinumab in psoriasis: Past, present, and future perspectives

Annals of the New York Academy of Sciences

Volumn 1222, Issue 1, 2011, Pages 30-39

  Yeilding, Newman ^a   Szapary, Philippe ^a   Brodmerkel, Carrie ^a   Benson, Jacqueline ^a   Plotnick, Michael ^b   Zhou, Honghui ^a   Goyal, Kavitha ^a   Schenkel, Brad ^b   Giles Komar, Jill ^a   Mascelli, Mary Ann ^c   Guzzo, Cynthia ^a  

^a CENTOCOR INC   (United States)

^b Janssen Global Services LLC   (United States)

^c LLC ^*  (United States)

Author keywords

Dermatology Life Quality Index (DLQI); Hospital Anxiety and Depression Score (HADS); Human monoclonal antibody (mAb); Psoriasis; Psoriasis Activity and Severity Index (PASI); Ustekinumab

Indexed keywords

CYCLOSPORIN; ETANERCEPT; ETRETIN; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; METHOTREXATE; PLACEBO; PROTEIN P35; PROTEIN P40; PSORALEN; USTEKINUMAB;

ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INCIDENCE; NONHUMAN; PATIENT SAFETY; PROTEIN TARGETING; PSORIASIS; PSORIASIS SEVERITY INDEX; QUALITY OF LIFE; TH1 CELL; TH17 CELL; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION;

MUS MUSCULUS;

EID: 79952828120     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.05963.x     Document Type: Article

References (50)

1. Nestle, F.O., D.H. Kaplan & J. Barker 2009. Psoriasis. N. Engl. J. Med. 361: 496-509.
2. Farber, E.M. & L. Nall 1998. Natural history and genetics. In Psoriasis, 3rd ed., H.H. Roenigk Jr. & Hi Maibach, Eds.: 114-115. Marcel Dekker. New York .
3. Christophers, E. 2001. Psoriasis-epidemiology and clinical spectrum. Clin. Exp. Dermatol. 26: 314-320.
4. Griffiths, C.E. & J.N. Barker 2007. Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271.
5. Mrowietz, U., J.T. Elder & J. Barker 2006. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch. Dermatol. Res. 298: 309-319.
6. Kimball, A.B., D. Gladman, J.M. Gelfand, et al 2008. National Psoriasis Foundation clinical consensus on psorias comorbidities and recommendations for screening. J. Am. Acad. Dermatol. 58: 1031-1042.
7. Eghlileb, A.M., E.E.G. Davies & A.Y. Finlay 2007. Psoriasis has a major secondary impact on the lives of family members and partners. Brit. J. Dermatol. 156: 1245-1250.
8. Basra, M.K.A. & A.Y. Finlay 2007. The family impact of skin diseases: the Greater Patient concept. Brit. J. Dermatol. 156: 929-937.
9. Picardi, A., E. Mazzotti & P. Pasquini 2006. Prevalence and correlates of suicide ideation among patients with skin disease. J. Am. Acad. Dermatol. 54: 420-426.
10. Horn, E.J., K.M. Fox, V. Patel, et al 2007. Association of patient-reported psoriasis severity with income and employment. J. Am. Acad. Dermatol. 57: 963-971.
11. Canadian Psoriasis Guidelines Committee, 2009. Canadian Guidelines for the Management of Plaque Psoriasis.
12. Stern, R.S., T. Nijsten, S.R. Feldman, et al 2004. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J. Investig. Dermatol. Symp. Proc. 9: 136-139.
13. Richards, H.L., D.G. Fortune & C.E.M. Griffiths 2006. Adherence to treatment in patients with psoriasis. J.E.A.D.V. 20: 370-379.
14. Nickoloff, B.J. & F.O. Nestle 2004. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J. Clin. Invest. 113: 1664-1675.
15. Hong, K., A. Chu, B.R. Lúdviksson, et al 1999. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J. Immunol. 162: 7480-7491.
16. Yawalker, N., S. Karlen, R. Hunger, et al 1998. Expression of interleukin-12 is increased in psoriatic skin. J. Invest. Dermatol. 111: 1053-1057.
17. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3: 133-146.
18. Oppmann, B., R. Lesley, B. Blom, et al 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
19. Aggarwal, S., N. Ghilardi, M-H. Xie, et al 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914.
20. Wilson, N.J., K. Boniface, J.R. Chan, et al 2007. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8: 950-957.
21. Cargill, M., S.J. Schrodi, M. Chang, et al 2007. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am. J. Hum. Genet. 80: 273-290.
22. Duerr, R.H., K.D. Taylor, S.R. Brant, et al 2006. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461-1463.
23. Capon, F., P. Di Meglio, J. Szaub, et al 2007. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122: 201-206.
24. Torti, D.C. & S.R. Feldman 2007. Interleukin-12, interleukin-23, and psoriasis: current prospects. J. Am. Acad. Dermatol. 57: 1059-1068. Comment and author reply.
25. Zaba, L.C., M. Suárez-Fariňas, J. Fuentes-Duculan, et al 2009. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J. Allergy Clin. Immunol. 124: 1022-1030.
26. Fishwild, D.M., S.L. O'Donnell, T. Bengoechea, et al 1996. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14: 845-851.
27. Luo, J., S.J. Wu, E.R. Lacy, et al 2010. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J. Mol. Biol. 402: 797-812.
28. Toichi, E., G. Torres, T.S. McCormick, et al 2006. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J. Immunol. 177: 4917-4926.
29. Kauffman, C.L., N. Aria, E. Toichi, et al 2004. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 antibody in subjects with plaque psoriasis. J. Invest. Dermatol. 123: 1037-1044.
30. Gottlieb, A.B., K.D. Cooper, T.S. McCormick, et al 2007. A phase I, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr. Med. Res. Opin. 23: 1081-1092.
31. Leonardi, C.L., A.B. Kimball, K.A. Papp, et al 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
32. Papp, K.A., R.G. Langley, M. Lebwohl, et al 2008. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684.
33. Griffiths, C.E., B.E. Strober, P. Van Der Kerkof, et al 2010. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N. Engl. J. Med. 362: 118-128.
34. Langley, R.G., S.R. Feldman, C. Han, et al 2010. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate to severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J. Am. Acad. Dermatol. 63: 457-465.
35. Lebwohl, M., K. Papp, C. Han, et al 2010. Ustekinumab improves health-related quality of life in patients with moderate to severe psoriasis: results from the PHOENIX 1 trial. Brit. J. Dermatol. 162: 137-146.
36. Airoldi, I., E. Di Carlo, C. Cocco, et al 2005. Lack of Il12rb2 signaling predisposes to spontaneous autoimmunity and malignancy. Blood 106: 3846-3853.
37. Novelli, F. & J.L. Casanova 2004. The role of IL-12, IL-23 and IFN-gamma in immunity to viruses. Cytokine Growth Factor Rev. 15: 367-377.
38. Murphy, C.A., C.L. Langrish, Y. Chen, et al 2003. Divergent pro- and anti-inflammatory roles for IL-23 and Il-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
39. Ciric, B., M. El-behi, R. Cabrera, et al 2009. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J. Immunol. 182: 5296-5305.
40. Rong, G., Y. Zhou, Y. Xiong, et al 2009. Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population. Clin. Exp. Immunol. 156: 217-225.
41. Berrebi, D., M. Besnard, G. Fromont-Hankard, et al 1998. Interleukin-12 expression is focally enhanced in the gastric mucosa of pediatric patients with Crohn's disease. Am. J. Pathol. 152: 667-672.
42. Cua, D.J., J. Sherlock, Y. Chen, et al 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
43. Shigehara, K., N Shijubo, M. Ohmichi, et al 2001. IL-12 and Il-18 are increased and stimulate IFN-γ production in sarcoid lungs. J. Immunol. 166: 642-649.
44. Sandborn, W.J., B.G. Feagan, R.N. Fedorak, et al 2008. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate to severe Crohn's disease. Gastroenterology 135: 1130-1141.
45. Gottlieb, A., A. Menter, A. Mendelsohn, et al 2009. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 373: 633-640.
46. Segal, B.M., C.S. Constantinescu, A. Raychaudhuri, et al 2008. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7: 796-804.
47. Dillon, S.B. 2010. New mechanisms and expanded indications for biologic therapies: a perspective on immunology research and development. Drug Disc. World Fall: 87-93.
48. Nograles, K.E., L.C. Zaba, E. Guttman, et al 2008. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br. J. Dermatol. 159: 1092-1102.
49. Zaba, L.C., I. Cardinale, P. Gilleaudeau, et al 2007. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J. Exp. Med. 204: 3183-3194.
50. Katugampola, R.P., V.J. Lewis & A.Y. Finlay 2007. The dermatology life quality index: assessing the efficacy of biological therapies for psoriasis. Brit. J. Dermatol. 156: 945-950.